ArticleFrontiers in pharmacology2025
The role of curcumin in modulating nutritional status and susceptibility to
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We performed a retrospective observational study of children aged 1-12 years at Beijing Luhe Hospital (September 2023-May 2024). Based on charted treatment, 160 patients were categorized into a curcumin-supplemented group (n = 80; standardized 95% curcuminoids, 20 mg/kg/day, with antibiotics) or a control group (n = 80; antibiotics alone). Outcomes included duration of fever/cough, hospitalization, severe complications, inflammatory markers-C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α)-pathogen-specific antibodies, and nutritional indices (body mass index [BMI], hemoglobin, serum albumin). Adverse events (AEs) were summarized. Results: Baseline characteristics were comparable between groups (all p > 0.05). The curcumin group had shorter fever (3.2 ± 1.1 vs. 4.5 ± 1.3 days, p = 0.01) and cough durations (5.4 ± 2.0 vs. 7.1 ± 2.5 days, p = 0.02), lower hospitalization rates (1.25% vs. 10.0%, p = 0.02), and fewer severe complications (2.5% vs. 12.5%, p = 0.03). Greater reductions were observed in CRP (-9.6 ± 5.1 vs. -1.8 ± 4.7 mg/L, p = 0.011), IL-6 (-15.1 ± 6.3 vs. -2.5 ± 5.8 pg/mL, p = 0.01), and TNF-α (-9.6 ± 5.4 vs. -1.7 ± 5.1 pg/mL, p = 0.03), with a larger increase in Conclusion: Curcumin might be a safe and well-tolerated adjunct to standard antibiotic therapy in children with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.